This session examines modern risk prediction models in transcatheter aortic valve implantation (TAVI). It presents novel scoring systems, the prognostic significance of cardiac damage extent and progression, and the impact of multivalvular disease, enhancing patient stratification and outcome prediction.

This session presents a qualitative exploration of women's experiences with cardiovascular disease, highlighting unique challenges throughout their care pathway from diagnosis to rehabilitation. It shares robust patient experience data and offers recommendations aimed at improving cardiovascular care tailored to women’s specific needs.

This session focuses on specific percutaneous coronary intervention strategies for spontaneous coronary artery dissection (SCAD) and related coronary anomalies. It covers clinical and therapeutic aspects of adult coronary aneurysms, woven coronary anomalies, innovative stent optimization techniques, microvascular dysfunction in takotsubo syndrome, and real-world management of SCAD...

Examine recent advances in coronary disease treatment focusing on drug-eluting stents versus drug-coated balloon strategies. This session presents real-world data on lesion preparation, sex-specific outcomes, physiological disease patterns, and procedural factors influencing PCI success.

Paris, France, 19−22 May 2026. The EuroPCR Course Directors have selected 3 major late-breaking trials that will be presented for the first time during EuroPCR 2026 and are set to impact practice worldwide. Among them is an individual participant data meta-analysis of 4 randomised controlled trials...

Alex Sticchi provides his take on the 3-year results of HOST-POLYTECH-ACS RCT which were presented by Hyo-Soo Kim during the ESC 2023 congress in Amsterdam.

Nicola Ryan provides her take on the BRIGHT-4 study, which was presented during AHA 2022 in Chicago, & simultaneously published in the Lancet.

This study was a randomised control trial designed to assess if bivalirudin plus a high dose infusion for 2-4 hours post PPCI was superior to unfractionated...

Authored by Hector Garcia-Garcia and Jorge Sanz-Sanchez, this article examines pivotal randomized clinical trials on drug-coated balloons in coronary artery disease. It highlights their role in managing in-stent restenosis, de novo small vessel lesions, and large vessel lesions while exploring future directions through ongoing trials.

Daniele Giacoppo reports and provides his perspective on the main results of the ambitious NEOMINDSET trial, presented by Pedro Lemos from the Hospital Israelita Albert Einstein, São Paulo, Brazil, during a Late Breaking Trials session at the ESC Congress 2025 in Madrid, and simultaneously published in the New...